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TNF-alfa in the HIV-1 related activation of apoptotic pro-
cess.
Conclusions: These results indicate that HIV-1 triggers
apoptosis in osteoblasts and HOBIT cells through the gp120
interaction with cell membrane and TNF-alfa induction sug-
gesting a novel mechanism in the HIV-1 related impairment
of the bone mass structure homeostasis.
doi:10.1016/j.ijid.2008.05.608
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Objective: To compare the Tumor Necrosis Factor-alpha
(TNF-) levels in HIV infected and uninfected healthy indi-
viduals and to evaluate TNF- release in the presence of
Vitamin D3, EB 1089 and methyl prednisolone in whole blood
cell cultures of HIV infected and uninfected individuals.
Methods: Plasma TNF- estimation: Blood was collected
from healthy blood donors (n = 66) & HIV infected patients
(n = 71) after their consent. Plasmawas separated and stored
at -700C till TNF- levels were measured.
Whole Blood cell assay: TNF- release was evaluated
in whole blood cell cultures of HIV infected (n = 13) and
uninfected individuals (n = 7) with and without modulators
such as Phytohaemagglutin (PHA) and Concanavalin-A (Con-
A); Methylprednisolone sodium succinate, Vitamin D3 and
EB1089 all of which have a potential affect on TNF- release.
Cytokine assay: The TNF- levels were estimated by
sandwich ELISA using R& D systems kit.
Results: There was a wide range of values of TNF- lev-
els in individuals of both uninfected and HIV infected groups.
There was a signiﬁcant decrease in the plasma TNF- levels
in HIV infected as compared to uninfected group. Stimula-
tion of whole blood cell cultures by Con A & PHA did not
show signiﬁcant differences in the TNF- release between
uninfected and HIV infected individuals. When stimulated
whole blood cultures were incubated in the presence of
methylprednisolone, vitamin D3 and EB 1089, only methyl-
prednisolone showed signiﬁcant difference in the inhibition
pattern as compared to others.
Conclusion: There is a wide scatter of individual plasma
TNF- values in patients & normal individuals. TNF- release
in the whole blood assays of normal & HIV patients also
showed a wide variation. Methylprednisolone exerted max-
imum inhibition in TNF- release as compared to other
modulators. Clinical follow up and longitudinal studies on
TNF- levels in patients could indicate its role in the pro-
gression of HIV to AIDS.
doi:10.1016/j.ijid.2008.05.609
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Approximately 10—40% of HIV-infected patients respond-
ing to antiretroviral therapy (ART) develop immune
restoration disease (IRD). It is thought that patients experi-
ence clinical deterioration as a result of an inﬂammatory
response to intact subclinical pathogens and/or residual
antigens.
Objective: To determine the incidence and risk factors
for the development of IRD in a cohort of severely immuno-
suppressed patients during successful treatment with ART
(triple therapy) at the UMMC clinic.
Methods: Patients were monitored and clinical data char-
acterized at weeks 0, 6, 12, 24 and 48 of ART from 47
patients with age, gender, ethnicity, CD4 T-cell count and
percentage, and plasma HIV RNA.
Results: The incidence of IRD in our cohort was 27.7%,
and the commonest IRD event was an exacerbation of symp-
toms (cervical lymphadenitis, lymphadenopathy and lymph
nodes evolving into abscesses or cold abscess enlargement)
associated with pre-existing infections with Mycobacterium
tuberculosis (MTb). Having a low baseline CD4 T-cell count
and percentage was a risk factor for developing IRD. TB IRD
occurred in patients who started ART within 6 weeks of TB
treatment.
Conclusion: Patients with advanced disease initiating ART
must be closely monitored in the ﬁrst 6 months for develop-
ment of IRD. In areas where MTB is endemic, TB IRD may
occur frequently and lead to diagnostic and therapeutic
challenges.
doi:10.1016/j.ijid.2008.05.610
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Objectives: A proportion of HIV patients beginning
antiretroviral therapy (ART) develop immune restoration
disease (IRD). Immunological characteristics of IRD were
